Further doubts raised over benefits of paracetamol for musculoskeletal pain
Researchers have renewed calls for an overhaul of advice on paracetamol in clinical guidelines for back pain and osteoarthritis, after finding it offers little benefit while potentially increasing the risk of liver damage.
Their study – a meta-analysis of thirteen randomised trials of paracetamol published in the BMJ – found paracetamol was no better than placebo for pain, disability and quality of life measures in the treatment of low back pain.
For hip or knee pain osteoarthritis, paracetamol did show a statistically significant effect in reducing pain and disability in the short term – but the researchers said the changes were not clinically important.
And although no increase in adverse events was reported with paracetamol compared with placebo, the team found patients taking paracetamol were four times as likely to have abnormal findings on liver function tests.
The Australian team concluded: ‘Paracetamol is ineffective in the treatment of low back pain and provides minimal short-term benefit for people with osteoarthritis.
‘These results support the reconsideration of recommendations to use paracetamol for patients with low back pain and osteoarthritis of the hip or knee in clinical practice guidelines.’
NICE advisors on osteoarthritis clinical guidelines were recently forced to back down on proposals to remove paracetamol as a first-line option for treatment of pain, after critics raised concerns it would increase prescribing of other, potentially more harmful drugs including NSAIDs and opioids.
UK academics, including GP Dr Christian Mallen, a professor in general practice at Keele University, said the latest findings re-open the debate over pharmacological management of musculoskeletal pain, and called for a shift to non-pharmacological approaches – particularly exercise.
‘The findings… emphasis that the time has come to shift our attention away from tablets as the default option for managing chronic musculoskeletal pain,’ they wrote in an editorial alongside the BMJ paper.
NICE confirmed it would be looking at paracetamol again as part of a wider review of drugs for osteoarthritis once the UK drugs regulator, the Medicines and Healthcare Products Regulatory Agency (MHRA), has completed a review of the safety of over-the-counter analgesics, including paracetamol.
A spokesperson said: ‘NICE has decided to wait until the MHRA’s work is complete before doing a review of all pharmacological management for osteoarthritis (including paracetamol). Looking at all of the relevant painkillers together, instead of just one, will then provide a comprehensive overview of this aspect of managing osteoarthritis and allow the findings of the MHRA work to be taken into account.’
A spokesperson for the MHRA told Pulse the safety review of painkillers available over the counter was likely to be completed ‘later in the year’.
The spokesperson said: ‘The MHRA has is considering the available evidence and what, if any, changes are needed in how these medicines are used in the non-prescription setting, and will seek advice from the independent scientific advisory body, the Commission on Human Medicines.
‘It is anticipated that the review will be completed later in the year at which point the outcome will be communicated.’